0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > ICAM-1

ICAM-1

ICAM-1 Molecule Information

Name:Intercellular adhesion molecule-1
Target Synonym:Major group rhinovirus receptor;Intercellular adhesion molecule 1;ICAM1;ICAM-1;CD_antigen=CD54
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:11
Lastest Research Phase:Approved

ICAM-1 Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
IC1-H52H5 Human Human ICAM-1 / CD54 Protein, His Tag
IC1-H52H5-structure
IC1-H52H5-sds
IC1-H5250 Human Human ICAM-1 / CD54 Protein, Fc Tag
IC1-H5250-structure
IC1-H5250-sds
IC1-H5250-elisa_1

ICAM-1 Molecule Synonym Name

ICAM1,BB2,CD54,P3.58

ICAM-1 Molecule Background

Inter-Cellular Adhesion Molecule 1 (ICAM-1) is also known as Cluster of Differentiation 54 (CD54), is a member of the immunoglobulin superfamily, and is a cell surface glycoprotein which is typically expressed in low concentrations on endothelial cells and cells of the immune system. The protein encoded by this gene is a type of intercellular adhesion molecule continuously present in low concentrations in the membranes of leukocytes and endothelial cells. Upon cytokine stimulation, the concentrations greatly increase. ICAM-1 can be induced by interleukin-1 (IL-1) and tumor necrosis factor alpha (TNF¦Á) and is expressed by the vascular endothelium, macrophages, and lymphocytes. ICAM-1 is a ligand for LFA-1 (integrin), a receptor found on leukocytes. When activated, leukocytes bind to endothelial cells via ICAM-1/LFA-1 and then transmigrate into tissues. ICAM-1 has been implicated in subarachnoid hemorrhage (SAH). Levels of ICAM-1 are shown to be significantly elevated in patients with SAH over control subjects in many studies. ICAM-1 expressed by respiratory epithelial cells is also the binding site for rhinovirus, the causative agent of most common colds.

ICAM-1 References

ICAM-1 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Tocopherol acetate DSE-9912 Approved Unknown Venous thromboembolism (VTE), Intermittent claudication, Diabetic retinopathy, Prevention of atherothrombotic events, Thrombosis Details

ICAM-1 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Enlimomab Phase Ⅲ Boehringer Ingelheim Stroke, Autoimmune diseases, Diabetes, Graft versus host disease, Intracranial thrombosis, Rejection of liver transplantation, Myocardia ischemia, Rheumatoid arthritis (RA), Burns, Asthma, Rejection of renal transplantation Details
GI-270384X GI-270384X; GI-270384 Phase Ⅱ GlaxoSmithKline Inflammatory bowel disease Details
BAY-Z-9700 BAY-Z-9700 Phase Ⅰ Bayer Rhinitis, Asthma Details
RhinoRx (Planet Biotechnology) Preclinical Planet Biotechnology HRV infection Details
ICM-3 ICM-3 Phase Ⅱ ICOS Corporation Psoriasis Details
tICAM-1-453 (Bayer) Phase Ⅰ Bayer HRV infection Details
Coxsackievirus A21 (Viralytics) CVA-21; V-937 Phase Ⅱ Viralytics Melanoma Details
Tyroserleutide CMS-024; YSL; alpha-BCP[7-9],CMS024 NDA Filing China Medical System Holdings Hepatocellular carcinoma (HCC) Details
Bersanlimab BI-505 Phase Ⅱ BioInvent International Multiple myeloma (MM) Details
Alicaforsen sodium AP-1007; AP-1431; AP-1450; AP-1451; ISIS-2302 NDA Filing Ionis Pharmaceuticals, Atlantic Healthcare Ulcerative colitis, Pouchitis, Inflammatory bowel disease Details
DZ-13 DZ-13; DZ13 Phase Ⅰ University of New South Wales, Royal Prince Alfred Hospital Basal cell carcinoma (BCC), Metastatic melanoma Details

This web search service is supported by Google Inc.

totop